Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy - PubMed (original) (raw)
Clinical Trial
Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy
Robert A Krance et al. Biol Blood Marrow Transplant. 2003 Apr.
Free article
Abstract
The CD45 antigen is present on all cells of the hematopoietic lineage. In some rodent models, lytic CD45 monoclonal antibodies (MAbs) induce complete marrow aplasia. In others, only transient myelolymphodepletion are observed, which are nonetheless sufficient to permit engraftment with fully allogeneic stem cells after otherwise ineffective doses of radiation. The in vivo effects of unconjugated cytolytic CD45 MAbs on myeloid and lymphoid cells in humans are unknown, so it is unclear if they could contribute in a similar way to conventional ablative or to nonmyeloablative preparative regimens used for stem cell transplantation (SCT). We therefore assessed the safety, myeloreductive activities, and lymphoreductive activities of the unconjugated rat anti-human CD45 MAbs, YTH25.4 and YTH54.12, in subjects who were to undergo SCT for advanced hematologic malignancy. The MAb pair bind to contiguous but nonoverlapping epitopes on CD45 and work synergistically to fix complement and recruit cellular lytic mechanisms. The MAbs were given in increasing doses up to 1600 microg/kg during 4 days, after which the patients began their conventional transplantation preparative regimen. The maximum tolerated dose of these MAbs, 400 microg/kg/d, produced marked reduction in circulating lymphoid and myeloid cells while largely sparing marrow progenitors. In 2 of 3 patients who had active leukemia at the time of study, the MAbs reduced the percentage of leukemic blast cells in bone marrow. Seven of 14 patients are disease free 610 to 1555 days post-SCT. The in vivo myeloreductive and lymphoreductive properties of lytic CD45 MAb in humans, therefore, closely parallel the activity seen in a murine model and, therefore, may be of similar value.
Copyright 2003 American Society for Blood and Marrow Transplantation
Similar articles
- Complement-fixing CD45 monoclonal antibodies to facilitate stem cell transplantation in mouse and man.
Brenner MK, Wulf GG, Rill DR, Luo KL, Goodell MA, Mei Z, Kuehnle I, Brown MP, Pule M, Heslop HE, Krance RA. Brenner MK, et al. Ann N Y Acad Sci. 2003 May;996:80-8. doi: 10.1111/j.1749-6632.2003.tb03236.x. Ann N Y Acad Sci. 2003. PMID: 12799286 Clinical Trial. - CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cells.
Wulf GG, Boehnke A, Chapuy B, Glass B, Hemmerlein B, Schroers R, Brenner MK, Truemper L. Wulf GG, et al. Haematologica. 2006 Jul;91(7):886-94. Haematologica. 2006. PMID: 16818275 - Cell surface antigen and molecular targeting in the treatment of hematologic malignancies.
Countouriotis A, Moore TB, Sakamoto KM. Countouriotis A, et al. Stem Cells. 2002;20(3):215-29. doi: 10.1634/stemcells.20-3-215. Stem Cells. 2002. PMID: 12004080 Review. - Anti-CD45 monoclonal antibody perfusion of human renal allografts prior to transplantation. A safety and immunohistological study. CD45 Study Group.
Goldberg LC, Bradley JA, Connolly J, Friend PJ, Oliveira DB, Parrott NR, Rodger RS, Taube D, Thick MG. Goldberg LC, et al. Transplantation. 1995 May 15;59(9):1285-93. Transplantation. 1995. PMID: 7762063 Clinical Trial.
Cited by
- A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice.
Saha A, Hyzy S, Lamothe T, Hammond K, Clark N, Lanieri L, Bhattarai P, Palchaudhuri R, Gillard GO, Proctor J, Riddle MJ, Panoskaltsis-Mortari A, MacMillan ML, Wagner JE, Kiem HP, Olson LM, Blazar BR. Saha A, et al. Blood. 2022 Mar 17;139(11):1743-1759. doi: 10.1182/blood.2021012366. Blood. 2022. PMID: 34986233 Free PMC article. - Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients.
Louis CU, Straathof K, Bollard CM, Gerken C, Huls MH, Gresik MV, Wu MF, Weiss HL, Gee AP, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. Louis CU, et al. Blood. 2009 Mar 12;113(11):2442-50. doi: 10.1182/blood-2008-05-157222. Epub 2008 Oct 29. Blood. 2009. PMID: 18971421 Free PMC article. Clinical Trial. - Antibody based conditioning for allogeneic hematopoietic stem cell transplantation.
Saha A, Blazar BR. Saha A, et al. Front Immunol. 2022 Oct 20;13:1031334. doi: 10.3389/fimmu.2022.1031334. eCollection 2022. Front Immunol. 2022. PMID: 36341432 Free PMC article. Review. - Conditioning Perspectives for Primary Immunodeficiency Stem Cell Transplants.
Shaw P, Shizuru J, Hoenig M, Veys P; IEWP-EBMT. Shaw P, et al. Front Pediatr. 2019 Nov 6;7:434. doi: 10.3389/fped.2019.00434. eCollection 2019. Front Pediatr. 2019. PMID: 31781522 Free PMC article. Review. - A Depleting Anti-CD45 Monoclonal Antibody as Isolated Conditioning for Bone Marrow Transplantation in the Rat.
Jäger MD, Vondran FW, Ramackers W, Röseler T, Schlitt HJ, Bektas H, Klempnauer J, Timrott K. Jäger MD, et al. PLoS One. 2016 May 3;11(5):e0154682. doi: 10.1371/journal.pone.0154682. eCollection 2016. PLoS One. 2016. PMID: 27139494 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous